Home›Compare›Embody vs FeelGood

Embody vs FeelGood: Which Is Better?

Head-to-head comparison of Embody and FeelGood based on our independent scoring across trust, value, experience, product range, and reputation — plus real pricing for the treatments they both offer.

Our Verdict

FeelGood scores higher overall in our independent evaluation (61/100 vs 54.9/100), leading on trust & safety, value, experience. Embody comes out ahead on product range, reputation. Embody has the lower entry price (from $69/mo vs $75/mo), so the better value depends on which treatment you need.

55
Embody
Below Average

Embody (joinem.co) is a low-price compounded GLP-1 storefront launched in late 2025 that also sells sermorelin and NAD+. It carries a BBB F rating and a high share of 1-star reviews.

Visit Embody
61

FeelGood is a 2026-launched, OpenLoop-powered GLP-1 brand whose promotional page offers compounded semaglutide from $89/mo and tirzepatide from $149/mo with no membership fee, alongside ED and 'longevity' microdose tirzepatide programs.

Visit FeelGood

Score Breakdown

DimensionEmbodyFeelGood
Overall Score54.9/10061/100 ✓
Trust & Safety30%48/10050/100 ✓
Value25%68/10080/100 ✓
Experience20%50/10065/100 ✓
Product Range15%62/100 ✓60/100
Reputation10%42/100 ✓40/100

At a Glance

Founded20252026
HeadquartersWilmington, DESheridan, WY
Publicly tradedNoNo
Treatment categories24
Treatments listed43
Starting price$69/mo$75/mo

Pricing Where They Compete

Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.

CategoryEmbodyFeelGood
Weight Loss / GLP-1$69–$199
Compounded Semaglutide
$75–$149
Compounded Semaglutide (injectable)
Longevity & Peptides$99–$199
NAD+ Injection or Nasal Spray
—

Embody

+Among the lowest advertised compounded GLP-1 prices: semaglutide from $79/mo, tirzepatide from $129/mo month-to-month
+Names its clinical network (OpenLoop Health) and four dispensing pharmacies
+Dose increases do not raise the price within a plan; HSA/FSA accepted
−BBB rating F (not accredited) for failing to respond to 23 complaints as of August 2026
−24% of ~8,600 Trustpilot reviews are 1-star, citing shipping delays, auto-renewal charges and refund difficulty
−Advertised landing-page prices conflict with the published terms ($79 vs $199/mo semaglutide; a $99-then-$299 starter plan)
Read the full Embody review →

FeelGood

+Promotional pricing is among the lowest tracked: compounded semaglutide $89/mo and tirzepatide $149/mo, with no membership fee and free shipping
+Clinical care is delivered through OpenLoop's established telehealth provider network
+Native iOS and Android apps plus 24/7 messaging support; HSA/FSA accepted
−Unsubstantiated marketing claims: '100,000+ patients' on a domain registered in February 2026, and a '2.4 years younger' epigenetic-age claim for microdose tirzepatide
−High-pressure sales tactics, including countdown timers, 'price increases soon' banners and 'only 9 spots left this month' prompts
−Prices vary across its own pages ($149 'starting' on the main site vs $89 on the offer page), so the price a patient gets depends on which landing page they arrive through
Read the full FeelGood review →

Embody vs FeelGood — FAQ

Is Embody better than FeelGood?

▾

FeelGood scores higher overall in our independent evaluation (61/100 vs 54.9/100), leading on trust & safety, value, experience. Embody comes out ahead on product range, reputation. Embody has the lower entry price (from $69/mo vs $75/mo), so the better value depends on which treatment you need.

Is Embody or FeelGood cheaper?

▾

Embody has the lower starting price (from $69/mo vs $75/mo for FeelGood). Starting prices are for the cheapest treatment each offers — compare the specific treatment you need, and check what each price includes.

What do Embody and FeelGood both offer?

▾

Both platforms treat Weight Loss / GLP-1, Longevity & Peptides. Embody covers 2 treatment categories total and FeelGood covers 4.

Still deciding?